
GSK to axe 99 positions at Memphis site
pharmafile | October 18, 2018 | News story | Manufacturing and Production | GSK, US, pharma
GlaxoSmithKline’s workforce on President’s Island in Memphis, US, is set to see the loss of 99 employees, as revealed in a WARN notice filed with the State Department of Labor.
The reason for the layoffs originates in the expiry of a contract manufacturing agreement by January 2019, which the company confirmed it would not be renewing.
“Due to this business change, GSK has filed a WARN (Worker Adjustment and Retraining Notification Act) notice with the Tennessee Department of Labor, to inform that we currently anticipate that 99 employees will be displaced between December 2018 and April 2019,” said GSK spokeswoman Caryn Previdi.
Specifically, the cuts will come into effect from 10 December to 2 April, according to the company’s WARN notice. After the 99 roles have been axed, 160 positions will remain at the site.
“We have a loyal and committed workforce at our Memphis site and this decision is no reflection on the team or their performance,” Previdi continued. “Teams at the Memphis site have demonstrated a great level of commitment to the business and we very much appreciate their dedication and hard work.”
Matt Fellows
Related Content

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …

Sharp invests $100m in US and EU manufacturing and packaging facilities
Sharp Services, a pharmaceutical packaging and sterile manufacturing specialist, has announced investments totalling $100m across …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …






